These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 32466249)

  • 1. Parkinson's Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization.
    Trifonova OP; Maslov DL; Balashova EE; Urazgildeeva GR; Abaimov DA; Fedotova EY; Poleschuk VV; Illarioshkin SN; Lokhov PG
    Diagnostics (Basel); 2020 May; 10(5):. PubMed ID: 32466249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of Metabolomics-Based Biomarker Research for Parkinson's Disease.
    Li X; Fan X; Yang H; Liu Y
    Mol Neurobiol; 2022 Feb; 59(2):1041-1057. PubMed ID: 34826053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of early diagnosis of Parkinson's disease and comprehensive economic analysis of the effect of its implementation].
    Gusev EI; Blokhin VE; Vartanov SA; Martynov MY; Katunina EA; Alesenko AV; Denisova IA; Pavlova EN; Polterovich VM; Kucheryanu VG; Shupik MA; Nodel MR; Kalinkin AL; Sokolov SA; Chubarova TV; Shakleina MV; Pronina TS; Ugryumov MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(1):9-20. PubMed ID: 33580755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms.
    Redenšek S; Dolžan V; Kunej T
    OMICS; 2018 Jan; 22(1):1-16. PubMed ID: 29356624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NMR Metabolomics Analysis of Parkinson's Disease.
    Lei S; Powers R
    Curr Metabolomics; 2013; 1(3):191-209. PubMed ID: 26078917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances and perspectives of metabolomics-based investigations in Parkinson's disease.
    Shao Y; Le W
    Mol Neurodegener; 2019 Jan; 14(1):3. PubMed ID: 30634989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of the Parkinson's KinetiGraph and clinical assessment in the management of Parkinson's disease.
    Chaudhuri KR; Hand A; Obam F; Belsey J
    J Med Econ; 2022; 25(1):774-782. PubMed ID: 35593687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolomics in Parkinson's disease.
    Troisi J; Landolfi A; Cavallo P; Marciano F; Barone P; Amboni M
    Adv Clin Chem; 2021; 104():107-149. PubMed ID: 34462054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current advances in metabolomic studies on non-motor psychiatric manifestations of Parkinson's disease (Review).
    Ciobanu AM; Ionita I; Buleandra M; David IG; Popa DE; Ciucu AA; Budisteanu M
    Exp Ther Med; 2021 Sep; 22(3):1010. PubMed ID: 34345292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated proteomics and metabolomics reveals metabolism disorders in the α-syn mice and potential therapeutic effect of Acanthopanax senticosus extracts.
    Fu J; Gao X; Lu Y; Lu F; Wang Y; Chen P; Wang C; Yuan C; Liu S
    J Ethnopharmacol; 2024 Jan; 318(Pt A):116878. PubMed ID: 37419226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the progression of Parkinson's disease: a metabolic network approach.
    Eckert T; Tang C; Eidelberg D
    Lancet Neurol; 2007 Oct; 6(10):926-32. PubMed ID: 17884682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease.
    Caudle WM; Bammler TK; Lin Y; Pan S; Zhang J
    Expert Rev Neurother; 2010 Jun; 10(6):925-42. PubMed ID: 20518609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease.
    de Aquino CH
    Front Neurol; 2021; 12():694329. PubMed ID: 34421799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omics Data and Their Integrative Analysis to Support Stratified Medicine in Neurodegenerative Diseases.
    La Cognata V; Morello G; Cavallaro S
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating nutriepigenomics in Parkinson's disease management: New promising strategy in the omics era.
    Razali K; Algantri K; Loh SP; Cheng SH; Mohamed W
    IBRO Neurosci Rep; 2022 Dec; 13():364-372. PubMed ID: 36590101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?
    Vuletić V; Rački V; Papić E; Peterlin B
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281267
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.